VolitionRx (NYSE:VNRX) Announces Earnings Results, Beats Estimates By $0.01 EPS

VolitionRx (NYSE:VNRX) posted its quarterly earnings results on Tuesday. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01, reports. VolitionRx had a negative return on equity of 7,185.73% and a negative net margin of 5,201.69%. The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.26 million.

VolitionRx Stock Performance

Shares of NYSE:VNRX opened at $0.76 on Friday. VolitionRx has a 12-month low of $0.58 and a 12-month high of $2.74. The stock’s 50 day moving average price is $0.85. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.69 and a quick ratio of 1.14.

Wall Street Analysts Forecast Growth

VNRX has been the subject of a number of research analyst reports. StockNews.com initiated coverage on VolitionRx in a report on Thursday, October 5th. They set a “sell” rating for the company. Cantor Fitzgerald lifted their price target on VolitionRx from $2.10 to $2.50 and gave the stock an “overweight” rating in a report on Thursday.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.